═══════════════════════════ CUSTOM SERVICES & ADD-ONS
Transparent Investment. Predictable Deliverables. ═══════════════════════════
Service Beyond Standard Tiers...
Advanced Capabilities for Complex Development Programs
Looking for our standard service tiers?
Need something beyond our standard Imaging Only, Standard Integration, or Comprehensive tiers? We offer extensive customization to match your unique research requirements. All custom services are quoted individually based on your specific needs. Our team will work with you to design the optimal study protocol and provide transparent pricing.
TABLE OF CONTENTS
[Large Animal Models] [Comparative Study Designs] [Behavioral Testing]
[Advanced Imaging] [Histopathology Add-Ons] [Study Extensions]
LARGE ANIMAL MODELS
Translational Research for Maximum Regulatory Impact
Discovery Imaging with the TITAN™ platform scales seamlessly from rodents to non-human primates. This ensures that when your program demands maximum translational relevance, the imaging data remains consistent and whole-body in scope.
AVAILABLE SPECIES
Dogs
(Beagle):
-
Regulatory Status: Standard regulatory toxicology species with deep historical background data.
-
Primary Utility: Excellent for cardiovascular and CNS therapies; the most commonly used non-rodent species for many traditional small-molecule toxicology programs, with extensive historical use in FDA-regulated drug development.
-
Anatomical Advantage: Highly predictable physiological responses and well-characterized metabolism.
Pigs
(Minipig, Yucatan, Göttingen):
-
Human Correlation: Highly similar cardiovascular anatomy and skin physiology to humans.
-
Primary Utility: The ideal model for medical devices, cardiovascular drugs, and transdermal delivery systems.
-
Regulatory Trend: Increasingly utilized in formal regulatory submissions for dermal toxicity.
Non-Human Primates (Cynomolgus, Rhesus)
-
Translational Gold Standard: Closest phylogenetic relationship to humans; most predictive for human metabolism.
-
Primary Utility: Critical for many biologics (mAbs), cell therapies, and gene therapy platforms when NHPs represent the most pharmacologically relevant species for human translation.
-
IND Impact: Essential for high-stakes IND-enabling studies where rodent reactivity is absent.
Rabbits:
-
Strategic Utility: A cost-effective bridge to larger species with established regulatory acceptance.
-
Primary Utility: Gold standard for ocular toxicity, dermal assessments, and reproductive toxicology.
-
Efficiency: Faster lead times for animal acquisition compared to NHPs or Beagles.
Other Models
-
Custom-sourced models available upon request.
-
Guinea Pigs and Hamsters
-
Sheep / Goats: Essential for orthopedic implants, pulmonary research, and cardiac valve safety. Their size allows for clinical-grade hardware use.
-
Ferrets: The gold standard for respiratory toxicology and certain CNS emesis studies.
-
Cats: Primarily used in specialized neuroscience or cardiovascular research where canine models aren't the right fit.
-
Camelids (Llamas/Alpacas): Growing in importance for nanobody development, with unique opportunities for high-value custom imaging of VHH biodistribution, tissue targeting, and associated tissue responses.
THE CASE FOR LARGE ANIMAL MODELS
Bridging the Gap to Clinical Success
While rodent studies provide essential preliminary data, large animal models are often the deciding factor in regulatory approval and successful human translation.
REGULATORY MANDATES:
Requirement for IND & Clinical Entry
-
Biologics & Complex Therapeutics: The FDA and EMA frequently mandate safety data in a non-rodent species for monoclonal antibodies, cell therapies, and gene platforms.
-
Medical Device Validation: Large animal physiology is required to demonstrate the safety and integration of stents, valves, and implantable hardware.
-
IND-Enabling Milestones: Crucial for bridging the "translational gap," providing the final layer of safety assurance required before First-in-Human (FIH) trials.
SUPERIOR HUMAN TRANSLATION:
Predictive Physiological Mapping
-
Clinical Symmetry: Highly conserved anatomy and metabolic pathways provide a more accurate prediction of human pharmacokinetics (PK).
-
Cardiovascular & Immune Fidelity: Large animal models offer a closer match to human heart rates, vascular pressures, and complex immune system responses.
-
Scale-Up Accuracy: Facilitates more precise dose-calculation for human clinical trials by mirroring human organ-to-body mass ratios.
DEEP MECHANISTIC INSIGHTS:
High-Resolution Data Acquisition
-
Spatial Resolution: Larger organ volumes allow the TITAN™ platform to capture granular details that are physically impossible to resolve in rodents.
-
Serial Longitudinal Sampling: Enables repeated blood draws and site-specific biopsies in a single subject, providing a continuous data stream without the need for animal sacrifice.
-
Advanced Monitoring: Integrated clinical monitoring, including continuous ECG, invasive blood pressure, and real-time functional imaging, provides a complete safety profile.
THE TITAN™ ADVANTAGE
Precision Imaging for High-Value Models
Large animal programs represent a significant capital commitment. TITAN™ is engineered to extract the maximum possible data density from every subject, ensuring your investment yields comprehensive, regulatory-grade insights.
MAXIMIZING PER-ANIMAL DATA VALUE:
-
Spatial Resolution: Larger organ volumes allow the TITAN™ platform to capture granular details that are physically impossible to resolve in rodents.
-
Serial Longitudinal Sampling: Enables repeated blood draws and site-specific biopsies in a single subject, providing a continuous data stream without the need for animal sacrifice.
-
Advanced Monitoring: Integrated clinical monitoring, including continuous ECG, invasive blood pressure, and real-time functional imaging, provides a complete safety profile.
ETHICAL DATA ACCELERATION (3Rs):
-
Reduction: Generate statistically superior data sets with fewer animals by using each subject as its own longitudinal control.
-
Refinement: Non-invasive whole-body monitoring significantly improves animal welfare and reduces the physiological stress variables that can skew results.
-
Replacement (Translational): High-fidelity large animal data reduces the risk of late-stage clinical failures, ensuring only the safest candidates move into human trials.
COMPREHENSIVE WHOLE-BODY COVERAGE:
-
Zero-Blind-Spot Analysis: Simultaneously assess all organ systems in a single session. We detect unexpected off-target toxicities that traditional "organ-of-interest" protocols miss.
-
No Pre-Selection Required: Eliminate the risk of overlooking toxicity in tissues you didn't think to sample. TITAN™ captures everything.
-
Integrated Pathological Review: All imaging data is supported by board-certified pathologist oversight to ensure clinical-grade interpretation.
REGULATORY-READY DELIVERABLES:
-
SEND-Compatible Data: Our data structures are pre-formatted for seamless integration into your electronic regulatory submissions.
-
Publication-Quality Visuals: High-resolution 3D reconstructions and figures suitable for IND submissions and peer-reviewed journals.
-
High-Quality Documentation: Comprehensive imaging reports that stand up to rigorous regulatory audit and peer review.
INVESTMENT CONSIDERATIONS:
Large animal programs represent a significant capital commitment. The TITAN™ Platform is engineered to extract the maximum possible data density from every subject, ensuring your investment yields comprehensive, regulatory-grade insights.
Strategic Cost Drivers:
-
Animal Acquisition: $3K–$15K per subject depending on species and source.
-
Specialized Husbandry: Dedicated housing, veterinary care, and longitudinal monitoring.
-
Imaging Logistics: Optimized for larger scanners and extended acquisition protocols.
-
Compliance: Rigorous regulatory documentation and audit-ready data trails.
Typical Study Parameters:
-
Cohort Size: 4–8 subjects depending on experimental model (Providing statistical power comparable to 12–14 rodents).
-
Study Duration: Standard 12–14 week timelines depending on experimental models.
-
Imaging Cadence: High-frequency longitudinal sampling recommended (e.g., Days 1, 3, 5, 7).
Pricing & Customization:
-
Quotes: Tailored to your specific protocol requirements, including species selection, study duration, and additional endpoints such as biomarkers or board-certified histopathology.
COMPARATIVE STUDY DESIGNS
De-Risk Population-Specific Safety Concerns
The FDA increasingly mandates diversity in preclinical populations. Factors such as age and sex can dramatically shift toxicity profiles. Early identification of at-risk populations informs clinical trial design and demonstrates a "Gold Standard" level of thoroughness to regulatory agencies.
SEX COMPARISON STUDIES:
Parallel Male & Female Cohorts
Identify sex-specific safety signals before they become clinical failures. By running parallel studies, you establish a baseline for differential drug metabolism and organ-specific toxicity.
Study Architecture:
-
Synchronized Protocols: Identical imaging, biomarkers, and endpoints across male and female animals.
-
Cohort Volume: Typically 12–14 males and 12–14 females (Total N=24–28).
-
Head-to-Head Analytics: Direct comparison of toxicity patterns and temporal onset between sexes.
Strategic Value & Regulatory Alignment:
-
IND Readiness: Meets frequent FDA requirements for data across both sexes.
-
Metabolic Insight: Accounts for hormonal influences on drug metabolism and clearance.
-
Differential Toxicity: Identifies drug classes with known sex-dependent risks, such as cardiotoxicity (QT prolongation) or hepatotoxicity.
Core Deliverables:
-
Susceptibility Mapping: Determine if one sex exhibits a higher toxicity risk.
-
Temporal Patterns: Identify if the onset of toxicity differs chronologically between sexes.
-
Clinical Predictivity: Data-backed insights to guide inclusion/exclusion criteria for Human Phase I trials.
Example Use Cases:
-
Hormone-targeted therapies.
-
Cardiovascular assessments (where QT prolongation is a variable).
-
Reproductive toxicity and broad-population therapeutics.
Investment:
Scaling to a dual-sex study essentially doubles the animal investment; however, per-animal pricing decreases through volume-based tiering.
AGE-BASED COMPARISON STUDIES:
Geriatric Safety & Susceptibility Mapping
Identify age-related differences in toxicity profiles by comparing young adult cohorts against aged animal models. As organ reserve diminishes with age, this study design is essential for drugs targeting elderly patient populations.
Study Architecture:
-
Parallel Age Cohorts: Simultaneous execution in young adults (e.g., 8–12 week mice) vs. aged models (e.g., 18–24 month mice).
-
Synchronized Protocols: Identical imaging, biomarkers, and endpoints across both groups to isolate age as the primary variable.
-
Specialized Handling: Extended acclimation periods and rigorous baseline health screenings to account for age-related variability.
Strategic Value & Regulatory Alignment:
-
Geriatric Safety Assessment: Directly addresses FDA interests for therapies targeting Alzheimer’s, Osteoarthritis, and Cardiovascular disease.
-
Metabolic Shift Detection: Identifies how age-related changes in liver and kidney function impact drug clearance and toxicity.
-
Organ Reserve Analysis: Evaluates if reduced physiological margins in elderly populations increase the risk of acute organ failure.
Core Deliverables:
-
Susceptibility Profiling: Determine if aged animals show toxicity at lower doses than young adults.
-
Differential Presentation: Identify if toxicity manifests through different pathways or organ systems in aging models.
-
Vulnerability Mapping: Pinpoint which specific organ systems are most at risk as a direct result of the aging process.
Example Use Cases:
-
Oncology: Evaluating safety in age-impacted physiological environments.
-
Neurodegenerative Therapies: Alzheimer's and Parkinson's treatments.
-
Chronic Disease: Long-term therapies where cumulative toxicity in aged tissue is a concern.
Investment:
Aged animals typically cost 2–3x more due to sourcing and long-term maintenance. Timelines may extend to ensure proper acclimation and health baseline stability.
COMBINED SEX & AGE STUDIES:
Comprehensive (2x2 Factorial Design)
The most comprehensive demographic safety profiling available. By analyzing four distinct cohorts simultaneously, this design provides the maximum level of regulatory rigor and investor confidence.
Study Architecture:
The 4-Cohort Matrix:
-
Young Males: (12–14 animals)
-
Young Females: (12–14 animals)
-
Aged Males: (12–14 animals)
-
Aged Females: (12–14 animals)
-
Total Power: 48–56 animals to ensure statistical significance across all subgroups.
-
Unified Protocols: Identical imaging and endpoints applied across the entire matrix to isolate demographic variables.
Strategic Value & Regulatory Alignment:
-
Demographic De-Risking: Provides the data necessary for drugs intended for broad, diverse patient populations.
-
Phase I Support: Data directly informs inclusion/exclusion criteria for early-stage human clinical trials.
-
High-Impact Evidence: Essential for publication in top-tier journals and for "bulletproof" investor due diligence.
Core Deliverables:
-
Interaction Effects: Discover if aging affects toxicity differently in males versus females (e.g., "Is an aged female more vulnerable than an aged male?").
-
Subpopulation Mapping: Identify the specific highest-risk demographic within the matrix.
-
Population-Specific Risks: A complete risk matrix covering the full spectrum of the target population.
Investment:
This represents the most comprehensive preclinical safety dataset possible. While it requires 4x the animal investment of a single cohort, it provides unparalleled regulatory support and clinical confidence.
Custom quotes are provided with volume pricing tiers applied to account for the larger animal counts.
.png)
SPECIES COMPARISON STUDIES:
Cross-Model Translational Insights
Build a complete translational dataset by running synchronized protocols in both rodent and large animal models simultaneously. This dual-model approach eliminates "missing link" data gaps that often stall IND applications.
.png)
Study Architecture:
-
Synchronized Protocols: Identical dosing regimens, adjusted for allometric scaling, to ensure data parity across species.
-
Parallel Execution: Mouse or Rat cohorts (N=12–14) running alongside Canine or Non-Human Primate cohorts (N=4–6).
-
Cohesive Endpoints: Identical imaging timepoints and biomarker assays for direct species-to-species comparison.
.png)
Strategic Value & Regulatory Alignment:
-
IND Package Strength: Demonstrates a comprehensive understanding of drug behavior across multiple biological systems.
-
De-Risking Findings: Quickly determines if a safety signal is a species-specific anomaly or a universal toxicity risk.
-
Concordance Mapping: Establishes the relationship between rodent data and large animal outcomes to strengthen regulatory submissions.
Core Deliverables:
-
Sensitivity Analysis: Identify which species is the most sensitive indicator for clinical risk.
-
Biomarker Correlation: Validate if imaging biomarkers correlate consistently across different physiological models.
-
Human Predictivity: Data-backed modeling to more accurately project first-in-human (FIH) response.
.png)
Example Use Cases:
-
Novel biologics with potential species-specific binding.
-
High-risk toxicity profiles requiring extra-stringent safety margins.
-
Complex metabolic pathways that vary significantly between rodents and larger mammals.
.png)
Investment:
Combined pricing for both studies offers a volume-based discount compared to running models independently, maximizing budget efficiency for comprehensive datasets.
AVAILABLE BEHAVIORAL TESTS:
EXAMPLES:
-
Morris Water Maze: The gold standard for spatial learning and memory. Assesses hippocampal function and cognitive impairment through quantitative measures like latency to platform and search strategy.
-
Open Field Test: A quick, 10-minute assessment of locomotor activity and anxiety-like behavior. Measures distance, velocity, and thigmotaxis (time in periphery).
-
Rotarod: Precision testing for motor coordination, balance, and endurance. Specifically designed to detect cerebellar or basal ganglia toxicity.
-
Elevated Plus Maze: A specialized anxiety assessment measuring time spent in open vs. closed arms; ideal for psychiatric drug development.
-
Novel Object Recognition: A low-stress assessment of non-spatial recognition memory and innate curiosity.
-
Grip Strength: Quantitative force measurement to detect neuromuscular weakness, neuropathy, or peripheral nerve toxicity.
-
Custom Behavioral Batteries: Our experts can design bespoke test sequences tailored to your specific therapeutic target or mechanism of action.
WHEN BEHAVIORAL TESTING ADDS VALUE:
-
CNS-Targeted Therapeutics: Essential for neurodegenerative disease drugs, psychiatric medications, and cognitive enhancers.
-
Mechanism-Based Concerns: Highly recommended for compounds known to cross the blood-brain barrier, targets expressed in the brain, or molecules with structural alerts for neurotoxicity.
-
Neurotoxic Risk Assessment: Critical for drug classes known to cause "chemobrain" (oncology), or those with structural alerts for blood-brain barrier penetration.
-
Quality of Life Metrics: Beyond efficacy, we assess how tumor burden or chronic dosing affects overall animal well-being and functional performance.
INTEGRATION WITH TITAN™:
The Power of Correlation:
By combining behavioral data with TITAN™ imaging, we answer the industry's most critical questions:
-
Does brain imaging detect tissue injury and/or structural damage before behavioral deficits appear?
-
Do functional impairments correlate with specific Noceravide uptake regions?
Multi-Modal Brain Assessment:
This is the most complete neurotoxicity assessment available. While imaging shows WHERE damage occurs, behavior demonstrates WHAT the functional impact is on the subject.
Study Design & Pricing:
Behavioral integration typically adds 1–2 weeks to the study timeline. Pricing is provided via a custom quote based on test selection, animal numbers, and testing frequency.
ADVANCED IMAGING MODALITIES
Multi-Modal Integration for Comprehensive Datasets
Pair TITAN™ SPECT/CT imaging with additional imaging modalities and technologies for the most comprehensive preclinical datasets available.
FUNCTIONAL MRI (fMRI):
Mapping Functional Connectivity & Regional Activation
-
The Technology: Non-invasive assessment of brain function via blood oxygenation level-dependent (BOLD) signals to detect functional connectivity and regional activation.
-
When It Adds Value: Critical for CNS-targeted therapeutics (antidepressants, cognitive enhancers) and mechanism of action studies to determine exactly which brain regions are affected.
-
TITAN™ Integration: While SPECT/CT shows WHERE tissue damage occurs, fMRI shows HOW brain function is altered as a result.
-
Protocol & Pricing: Includes baseline and post-treatment resting-state or task-based fMRI. Custom quote based on frequency and analysis complexity.
CARDIAC MRI:
High-Resolution Structural & Functional Cardiotoxicity Screening
-
The Technology: Precise imaging of cardiac structure (ejection fraction, wall motion) and detection of myocardial fibrosis or edema.
-
When It Adds Value: Essential for cardiotoxic drug classes (anthracyclines, TKIs) or compounds with QT prolongation concerns.
-
TITAN™ Integration: Tri-modal assessment combining SPECT (cell-death signal), Cardiac MRI (functional impact), and clinical biomarkers (Troponin).
-
Protocol: Baseline and serial imaging (e.g., Days 1, 3, 5, 7) with optional continuous ECG monitoring. Custom quote based on frequency and analysis complexity.
ULTRASOUND IMAGING:
Real-Time Anatomical & Vascular Hemodynamics
-
The Technology: Real-time imaging of soft tissue and Doppler assessment of blood flow for immediate physiological feedback.
-
When It Adds Value: Cost-effective monitoring of organ size (hepatomegaly), vascular changes, and accurate tumor volume measurements.
-
TITAN™ Integration: Serves as a frequent, non-invasive anatomical and functional complement to SPECT/CT.
BIOLUMINESCENCE IMAGING (BLI):
Simultaneous Tracking of Efficacy & Systemic Toxicity
-
The Technology: Optical tracking of luciferase-expressing cells for high-throughput tracking of tumor burden or infection.
-
The "Therapeutic Index" Study: BLI tracks efficacy (tumor shrinkage) while SPECT/CT tracks toxicity (tissue damage) in the same animals.
-
Typical Protocol: Serial BLI (2-3x per week) integrated with SPECT/CT at key intervals (Days 1, 3, 5, 7) to optimize the therapeutic window.
DUAL SIMULTANEOUS ISOTOPIC LABELING:
Correlative Biodistribution & Direct Tissue Injury Analysis
-
The Technology: Use two radioisotopes simultaneously to track candidate biodistribution while TITAN™ assesses candidate-associated tissue damage and injury in the same subject.
-
Scientific Insight: Directly correlate candidate accumulation with injury to determine if toxicity is exposure-driven (on-target) or mechanistic (off-target).
-
Strategic Value: Supports regulatory discussions regarding dose optimization and formulation development by proving the temporal relationship between exposure and injury.
HISTOPATHOLOGY & TISSUE ANALYSIS ADD-ONS:
Microscopic Validation of Imaging Findings
While the TITAN™ Comprehensive tier includes H&E and TUNEL staining as standard, these specialized add-ons provide the deeper mechanistic insights required for regulatory success.
FOUNDATIONAL ANALYSIS:
Included in Comprehensive Tier
-
H&E (Hematoxylin & Eosin): The fundamental diagnostic stain used to evaluate general tissue morphology and identify structural abnormalities, inflammation, or necrosis.
-
TUNEL Staining: A highly sensitive method for detecting and confirming apoptotic DNA fragmentation, providing cellular-level proof of the cell-death signals captured by Noceravide™ imaging.
-
Unstained Sections: Two (2) slides per tissue are provided for immediate use or baseline records.
IMMUNOHISTOCHEMISTRY (IHC)
ADD-ONS:
Targeted Protein Detection & Cell-Type Identification
-
Common Markers:
-
Ki-67 / PCNA: Proliferative indices.
-
Cleaved Caspase-3: Apoptosis (complements TUNEL).
-
CD68 / F4/80: Macrophage infiltration and inflammation.
-
Cytokeratin: Epithelial cell markers.
-
-
Strategic Application: Identify which specific cell types are affected and confirm your mechanism of action (MoA) with mechanistic data.
-
Pricing: Custom quote per marker and tissue. Typical investment: $3K–$8K contingent on study and markers.
SPECIAL HISTOPATHOLOGY STAINS:
Targeted Visualization of Fibrosis, Lipids, and Deposits
-
Masson’s Trichrome: Detects fibrosis and collagen; essential for chronic heart, liver, or kidney toxicity studies.
-
Oil Red O: Lipid staining for frozen sections; detects and quantifies steatosis (fatty liver).
-
PAS (Periodic Acid-Schiff): Stains glycogen and basement membranes; critical for kidney glomerular studies.
-
Prussian Blue: Detects iron deposition and hemosiderin (blood breakdown products).
-
Congo Red: Detects amyloid deposits and protein aggregation.
-
Clinical Rationale: These specialized stains provide the classic pathology evidence required by regulatory bodies to characterize specific organ toxicities.
-
Pricing: Custom quote per marker and tissue. Typical investment: $2K–$5K per stain depending on complexity and contingent on study and markers.
ADDITIONAL UNSTAINED SECTIONS:
Future-Proofing Your Study for Retrospective Analysis
-
Technical Overview: Tissue sections are professionally cut and mounted on slides but left unstained. This allows for specialized staining at a later date or at an external facility.
-
Strategic Application:
-
Flexibility: Ideal when the specific stains required are uncertain at the start of the study.
-
Collaboration: Enables shipping ready-to-stain slides to collaborating laboratories or specialized CROs.
-
Budget Management: Allows for the deferral of staining costs until specific regions of interest are identified via imaging.
-
-
Study Integration: While the TITAN™ Comprehensive tier includes 2 unstained sections per tissue, requesting additional slides ensures sufficient material remains for exhaustive retrospective analysis.
-
Pricing: Modest additional cost. Typical investment: $1K–$3K based on section volume and tissue count contingent on study demands.
STUDY EXTENSIONS & MODIFICATIONS
Agile Protocols for Complex Research Demands
While our standard protocols are optimized for rapid throughput, we offer full flexibility to extend or modify your study when your specific research objectives require it.
ADDITIONAL IMAGING TIMEPOINTS:
Capturing Late-Onset Toxicity & Assessing Reversibility
-
Technical Overview: Extend your protocol beyond the standard Day 5 or Day 7 endpoints to include custom intervals such as Days 10, 14, 21, or monthly imaging.
-
Scientific Rationale: *Delayed Toxicity: Essential for compounds with slow-onset effects (e.g., certain nephrotoxicants) that may take 2–3 weeks to manifest.
-
Resolution & Recovery: Monitor the animal's ability to recover after treatment cessation—a critical data point for clinical trial safety margins.
-
Pricing: Provided per additional timepoint; includes imaging, advanced analysis, and continued animal housing/monitoring. Custom quotes based on frequency and analysis complexity.
EXTENDED STUDY DURATION:
Long-Term Survival & Chronic Disease Assessments
-
Technical Overview: Continue monitoring beyond the standard endpoint for survival studies, tumor progression, or maximum tolerated dose (MTD) determination.
-
Strategic Application: *Oncology: Tumor models often require 4–6 months of tracking for efficacy vs. toxicity analysis.
-
Chronic Exposure: Assess the long-term consequences of acute exposure or the cumulative effects of chronic administration.
-
Includes: Daily clinical observations, longitudinal weight tracking, and serial imaging throughout the extended duration.
MULTI-DOSE STUDIES:
Parallel Dose-Response & NOAEL Determination
-
Technical Overview: Run 2–3 dose levels (Low, Mid, High) in parallel cohorts to establish clear dose-response relationships and identify the No-Observed-Adverse-Effect Level (NOAEL).
-
Strategic Rationale: Regulatory bodies prioritize dose-response data to understand narrow therapeutic windows and support Phase I starting dose selection.
-
Pricing Advantage: More cost-effective than separate studies due to shared tracer synthesis, setup costs, and volume pricing. Typically yields 15–25% savings vs. independent runs.
FLEXIBLE STUDY DESIGN:
Bespoke Paradigms for Targeted Scientific Inquiry
-
Custom Dosing: Accommodating intermittent schedules, loading doses, and multiple routes of administration (IV, IP, Oral, Topical).
-
Combination Therapies: Identify synergistic toxicity or unique safety signals by comparing Drug A + Drug B vs. monotherapies.
-
Intervention & Rescue: Test protective agents or rescue therapies by monitoring "Baseline → Toxicity → Intervention → Recovery."
-
Disease Models: Assess toxicity in clinically relevant subjects, including aged, diabetic, or tumor-bearing animals.
READY TO DISCUSS YOUR CUSTOM NEEDS?
Collaborative Protocol Development with Our Scientific Team
Every research program is unique. Our team of PhD scientists will work with you to design the optimal study protocol, providing the transparent, competitive pricing and technical expertise your project demands.
WE'RE HERE TO HELP:
Talk with our scientists about your specific requirements, including:
-
Your compound's development stage and regulatory goals.
-
Study design recommendations tailored to your models.
-
Integration strategies with your existing preclinical program.
QUESTIONS ABOUT CUSTOM SERVICES?
Visit our comprehensive FAQ for answers regarding large animal logistics, behavioral protocols, and study extension options.
Questions? Contact Us:
Phone: (414) 465-8654
Email: inquiries@durametrix.com
Our team reviews all inquiries daily. You can expect a response from a technical lead by the next business day.